<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128942</url>
  </required_header>
  <id_info>
    <org_study_id>SPR001-205</org_study_id>
    <nct_id>NCT05128942</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, PK, and Exploratory PD of Tildacerfont in Children With CAH</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of SPR001 (Tildacerfont) in Children Aged 6 to 17 Years With Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spruce Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spruce Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigation of the safety of Tildacerfont in pediatric subjects with CAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to evaluate the safety of Tildacerfont in pediatric subjects with CAH.&#xD;
      Treatment will consist of 14 days of continuous dosing followed by safety follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be assigned to treatment cohorts by age.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with TEAE as assessed by CTAE version 5</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate safety of tildacerfont in pediatric subjects with CAH as measured by number of subjects with adverse events following dosing by CTAE version 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>14 days</time_frame>
    <description>To determine the pharmacokinetics (PK) of tildacerfont in pediatric subjects with CAH as measured by area under the plasma concentration versus time curve (AUC) of tildacerfont following dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability assessed using a 5-point hedonic scale following dosing</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the acceptability of the granule formulation of tildacerfont in pediatric subjects using a 5-point hedonic scale following dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability (smell taste, texture) assessed using a 5-point hedonic scale following dosing</measure>
    <time_frame>14 days</time_frame>
    <description>To assess the palatability of the granule formulation of tildacerfont in pediatric subjects using a 5-point hedonic scale to compare the product smell, taste, mouth feel following dosing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <condition>21-OHD</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Age 11-17 Treatment with Tildacerfont</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tildacerfont administered daily for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Age 11-17 Treatment with Tildacerfont</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tildacerfont administered daily for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Age 6-10 Treatment with Tildacerfont</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tildacerfont administered daily for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tildacerfont</intervention_name>
    <description>Oral granule formulation taken once daily in combination with glucocordicoid therapy.</description>
    <arm_group_label>Cohort 1: Age 11-17 Treatment with Tildacerfont</arm_group_label>
    <arm_group_label>Cohort 2: Age 11-17 Treatment with Tildacerfont</arm_group_label>
    <arm_group_label>Cohort 3: Age 6-10 Treatment with Tildacerfont</arm_group_label>
    <other_name>SPR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects aged 6 to 17 years&#xD;
&#xD;
          -  Diagnosis of CAH due to 21-OHD and/or elevated 17-OHP requiring ongoing GC replacement&#xD;
             since diagnosis&#xD;
&#xD;
          -  Stable dose of GC replacement for at least 1 month prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CAH not due to 21-OHD&#xD;
&#xD;
          -  History of bilateral adrenalectomy or hypopituitarism&#xD;
&#xD;
          -  Current treatment with dexamethasone&#xD;
&#xD;
          -  Clinically significant unstable medical conditions, illness, or chronic diseases&#xD;
&#xD;
          -  History of active bleeding disorders&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dennis Aguiling</last_name>
    <phone>4253014314</phone>
    <email>dvaguiling@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Houston</last_name>
    <phone>4154048838</phone>
    <email>shouston@sprucebiosciences.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>CAH</keyword>
  <keyword>Adrenal Disorder</keyword>
  <keyword>Congenital Adrenal Hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

